Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Edan

Showing results (11-20 of 149) with videos related to

Pageof 15
Sort By:
BMC Neurology|July 31, 2015
Spinal cord hemorrhage in a patient with neurosarcoidosis on long-term corticosteroid therapy: case reportBenoit Pegat, Sophie Drapier, Xavier Morandi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 28, 2014
Improving the quality of life of multiple sclerosis patients through coping strategies in routine medical practiceRichard Devy, Philippe Lehert, Etienne Varlan, et al.
European Journal of Neurology|May 26, 2022
Disability Progression in Multiple Sclerosis Patients using Early First-line TreatmentsMathilde Lefort, Sandra Vukusic, Romain Casey, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2006
Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assayCatherine Massart, Jacqueline Gibassier, Joël Oger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 20, 2015
Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active diseaseRichard Gonsette, Marc Debouverie, Christian Sindic, et al.
International Journal of Health Geographics|September 23, 2017
Small-area distribution of multiple sclerosis incidence in western France: in search of environmental triggersKarima Hammas, Jacqueline Yaouanq, Morgane Lannes, et al.
Pharmacoepidemiology and Drug Safety|October 20, 2020
Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity scoreMathilde Lefort, Yohann Foucher, Remi Lenain, et al.
Studies in Health Technology and Informatics|November 17, 2006
A model for a regional health information network sharing clinical information between professionals in BritannyMarc Cuggia, Nicolas Herry, Delphine Rossille, et al.
Medical Image Analysis|April 14, 2015
Diffusion MRI abnormalities detection with orientation distribution functions: a multiple sclerosis longitudinal studyOlivier Commowick, Adil Maarouf, Jean-Christophe Ferré, et al.
Journal of Neurology|February 22, 2015
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational studyEmmanuelle Le Page, Véronique Deburghgraeve, Marie-Antoinette Lester, et al.
Pageof 15

Showing results (11-20 of 149) with videos related to

Sort By:
Pageof 15
BMC Neurology|July 31, 2015
Spinal cord hemorrhage in a patient with neurosarcoidosis on long-term corticosteroid therapy: case reportBenoit Pegat, Sophie Drapier, Xavier Morandi, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 28, 2014
Improving the quality of life of multiple sclerosis patients through coping strategies in routine medical practiceRichard Devy, Philippe Lehert, Etienne Varlan, et al.
European Journal of Neurology|May 26, 2022
Disability Progression in Multiple Sclerosis Patients using Early First-line TreatmentsMathilde Lefort, Sandra Vukusic, Romain Casey, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 25, 2006
Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assayCatherine Massart, Jacqueline Gibassier, Joël Oger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 20, 2015
Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active diseaseRichard Gonsette, Marc Debouverie, Christian Sindic, et al.
International Journal of Health Geographics|September 23, 2017
Small-area distribution of multiple sclerosis incidence in western France: in search of environmental triggersKarima Hammas, Jacqueline Yaouanq, Morgane Lannes, et al.
Pharmacoepidemiology and Drug Safety|October 20, 2020
Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity scoreMathilde Lefort, Yohann Foucher, Remi Lenain, et al.
Studies in Health Technology and Informatics|November 17, 2006
A model for a regional health information network sharing clinical information between professionals in BritannyMarc Cuggia, Nicolas Herry, Delphine Rossille, et al.
Medical Image Analysis|April 14, 2015
Diffusion MRI abnormalities detection with orientation distribution functions: a multiple sclerosis longitudinal studyOlivier Commowick, Adil Maarouf, Jean-Christophe Ferré, et al.
Journal of Neurology|February 22, 2015
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational studyEmmanuelle Le Page, Véronique Deburghgraeve, Marie-Antoinette Lester, et al.
Pageof 15